Coherus BioSciences (CHRS) Earnings Date, Estimates & Call Transcripts → Urgent Nvidia Warning (From Altimetry) (Ad) Free chrs Stock Alerts $2.27 +0.10 (+4.61%) (As of 05/3/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateMay. 9After Market ClosesConfirmedActual EPS (Mar. 13) -$0.72 Missed By -$0.39 Consensus EPS (Mar. 13) -$0.33 Get Coherus BioSciences Earnings AlertsEnter your email address below to receive the latest news and earnings results for CHRS and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCHRS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CHRS Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. Coherus BioSciences Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:($0.37) EPSNext Year EPS Consensus Estimate: $0.41 EPSCHRS Earnings Date and InformationCoherus BioSciences last released its earnings data on March 13th, 2024. The biotechnology company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.39. The business had revenue of $91.52 million for the quarter, compared to analysts' expectations of $105.30 million. Coherus BioSciences has generated ($2.57) earnings per share over the last year (($2.57) diluted earnings per share). Earnings for Coherus BioSciences are expected to grow in the coming year, from ($0.37) to $0.41 per share. Coherus BioSciences has confirmed that its next quarterly earnings report will be published on Thursday, May 9th, 2024. Coherus BioSciences will be holding an earnings conference call on Thursday, May 9th at 5:00 PM Eastern. Interested parties can register for or listen to the call.. Read More Coherus BioSciences Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/9/2024Confirmed)------- 3/13/2024Q4 2023($0.33)($0.72)($0.39)($0.73)$105.30 million$91.52 million11/6/2023Q3 2023($0.45)($0.38)+$0.07($0.35)$80.13 million$74.57 million8/2/2023Q2 2023($0.66)($0.49)+$0.17($0.49)$50.83 million$58.72 million5/8/2023Q1 2023($0.77)($0.89)($0.12)($0.82)$50.73 million$32.44 million3/6/2023Q4 2022($0.64)($0.76)($0.12)($0.76)$45.72 million$45.35 million 11/8/2022Q3 2022($0.79)($1.11)($0.32)($1.11)$57.23 million$45.42 million Get the Latest News and Ratings for CHRS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter. 8/4/2022Q2 2022($0.96)($0.65)+$0.31($0.65)$58.00 million$60.15 million 5/5/2022Q1 2022($0.80)($1.24)($0.44)($1.24)$68.07 million$60.12 million2/17/2022Q4 2021($0.61)($0.60)+$0.01($0.60)$83.32 million$73.37 million 11/7/2021Q3 2021($0.22)($0.34)($0.12)($0.49)$86.96 million$82.50 million 8/5/2021Q2 2021($0.25)($0.40)($0.15)($0.40)$82.65 million$87.64 million 5/6/2021Q1 2021$0.09($2.37)($2.46)($2.37)$97.87 million$83.03 million Coherus BioSciences Earnings - Frequently Asked Questions When is Coherus BioSciences's earnings date? Coherus BioSciences has confirmed that its next quarterly earnings data will be published on Thursday, May 9th, 2024. Learn more on CHRS's earnings history. Did Coherus BioSciences beat their earnings estimates last quarter? In the previous quarter, Coherus BioSciences (NASDAQ:CHRS) missed the analysts' consensus estimate of ($0.33) by $0.39 with a reported earnings per share (EPS) of ($0.72). Learn more on analysts' earnings estimate vs. CHRS's actual earnings. How much revenue does Coherus BioSciences generate each year? Coherus BioSciences (NASDAQ:CHRS) has a recorded annual revenue of $257.24 million. How much profit does Coherus BioSciences generate each year? Coherus BioSciences (NASDAQ:CHRS) has a recorded net income of -$237.89 million. CHRS has generated -$2.57 earnings per share over the last four quarters. What is Coherus BioSciences's EPS forecast for next year? Coherus BioSciences's earnings are expected to grow from ($0.37) per share to $0.41 per share in the next year. More Earnings Resources from MarketBeat Related Companies: FENC Earnings BDTX Earnings STRO Earnings ADVM Earnings IVVD Earnings GLUE Earnings ELEV Earnings CMPX Earnings PSTX Earnings XFOR Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Apple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings? This page (NASDAQ:CHRS) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCUrgent Nvidia WarningAltimetryGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceForget Nvidia. This is the future of AIPorter & CompanyThe asset beating inflation by 4xColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
